| Literature DB >> 33517823 |
Matias Hemmilä1, Inari Laaksonen1, Markus Matilainen2, Antti Eskelinen3, Jaason Haapakoski4, Ari-Pekka Puhto5, Jukka Kettunen6, Konsta Pamilo3, Keijo T Mäkelä1.
Abstract
Background and purpose - The use of crosslinked polyethylene in total hip arthroplasty (THA) has decreased wear remarkably. It has been suggested that the antioxidative effects of vitamin E may enhance the wear properties of polyethylene even further. This study evaluates revision rates between vitamin E-infused polyethylene liners (E1 and E-poly, ZimmerBiomet, Warsaw, IN, USA) versus moderately crosslinked polyethylene (ModXLPE) liners from the same manufacturer used in primary THA.Patients and methods - We conducted a study based on data from the Finnish Arthroplasty Register. The study group consisted of 2,723 THAs with a vitamin E-infused liner and a reference group of 2,707 THAs with a moderately crosslinked polyethylene liner. Survivorship, revision risk, and re-revision causes were compared between groups.Results - The 7-year survival of the vitamin E-infused polyethylene liner group and of the reference group with revision for any reason as the endpoint was comparable (94% [95% CI 92.9-94.9] and 93% [CI 91.9-93.9], respectively). The adjusted hazard ratio (HR) for any revision was similar between the groups (0.7 [CI 0.4-1.1]). When revision for aseptic loosening was studied as the endpoint, the survival for the study group was 99% (CI 98.6-99.4) and for the reference group 99% (CI 98.7-99.5), and the risk of revision was comparable between the study groups (HR 1.3 [CI 0.7-2.5]).Interpretation - After an observation period of 7 years vitamin E-infused liners shows results equal to results obtained with crosslinked polyethylene liners.Entities:
Year: 2021 PMID: 33517823 PMCID: PMC8231410 DOI: 10.1080/17453674.2021.1879513
Source DB: PubMed Journal: Acta Orthop ISSN: 1745-3674 Impact factor: 3.717
Components used, number (%)
| VEPE group | Reference group | |
| Cup designs | ||
| Biomex | 0 (0) | 56 (2) |
| Exceed | 506 (19) | 312 (12) |
| G7 | 501 (18) | 211 (8) |
| Regenerex | 741 (27) | 6 (0.2) |
| Vision Ringloc | 975 (36) | 2,122 (78) |
| Stem designs | ||
| Bi-Metric | 1,143 (42) | 2,459 (91) |
| CDH | 3 (0.1) | 20 (0.7) |
| Echo | 1,357 (50) | 174 (6) |
| Reach | 18 (1) | 4 (0.2) |
| Taperloc | 202 (7) | 50 (2) |
ZimmerBiomet, Warsaw, IN, USA.
Demographic data of study population, number (%), unless stated otherwise
| Data | VEPE group | Reference group |
|---|---|---|
| Mean age, years (SD) | 67 (10) | 64 (9) |
| BMI (SD) | 29 (5) | 28 (5) |
| Male sex | 1,341 (49) | 1,357 (50) |
| Diagnosis | ||
| Primary osteoarthritis | 2,328 (86) | 2,274 (84) |
| Rheumatoid arthritis | 59 (2) | 83 (3) |
| Other | 336 (12) | 350 (13) |
| Femoral head size | ||
| 28 | 4 (0.2) | 2,229 (82) |
| 32 | 321 (12) | 284 (11) |
| 36 | 2,398 (88) | 194 (7) |
| Femoral head material | ||
| Ceramic | 822 (30) | 220 (8) |
| Metal | 1,901 (70) | 2,487 (92) |
| Status at end of follow up | ||
| Not revised | 2,571 (94) | 2,348 (87) |
| Revised | 152 (6) | 359 (13) |
| Operation year | ||
| 2000–2008 | 6 (0.2) | 2,376 (88) |
| 2009–2017 | 2,717(99.8) | 331 (12) |
Fractures, avascular necrosis, osteoarthritis due to hip dysplasia, tumors, congenital hip dislocation, Mb Legg–Calve–Perthes, femoral head epiphysiolysis.
Excluding death.
Figure 2.Kaplan–Meier survival for VEPE group and Reference group with revision for any reason as the endpoint. 95% CI levels presented in blue and red.
Revision risk according to Cox regression model with all revisions as endpoint
| Group | HR (95% CI) | p-value |
|---|---|---|
| VEPE group vs. Reference group | 0.69 (0.44–1.1) | 0.09 |
| Adjusting variables | ||
| Left vs. right side | 0.98 (0.82–1.2) | 0.8 |
| Female vs. male | 0.99 (0.83–1.2) | 0.9 |
| Ceramic vs. metal head | 1.2 (0.90–1.5) | 0.3 |
Adjusting variables stratified by head size, age group, and diagnosis. HR = hazard ratio. CI = confidence interval.
Figure 3.Kaplan–Meier survival for VEPE group and Reference group with revision for osteolysis, liner wear, liner breakage, loosening of the cup, and other reason as an endpoint. 95% CI levels presented in blue and red.
Indication for revision prior to data content revision (May 15, 2014) of Finnish Register, number (%)
| Main reason for revision | VEPE group | Reference group |
| Aseptic loosening | ||
| Cup and stem | 0 (0) | 2 (1) |
| Cup | 9 (10) | 10 (4) |
| Stem | 2 (2) | 9 (4) |
| Infection | 10 (11) | 17 (7) |
| Dislocation | 27 (30) | 103 (46) |
| Component malposition | 7 (8) | 22 (10) |
| Fracture | 24 (26) | 23 (10) |
| Component breakage | 0 | 2 (1) |
| Other | 12 (13) | 41 (18) |
No data available concerning indication for revision from 36 revisions.
Revision risk according to Cox regression model with revision for osteolysis, liner wear, liner breakage, loosening of the cup (and other reason before May 15, 2014) as endpoint
| Group | HR (95% CI) | p-value |
|---|---|---|
| VEPE group vs. Reference group | 1.3 (0.71–2.5) | 0.4 |
| Adjusting variables | ||
| Female vs. male | 1.0 (0.71–1.5) | 0.9 |
| Other diagnoses vs. RA | 0.96 (0.35–2.6) | 0.9 |
| Primary OA vs. RA | 0.85 (0.34–2.1) | 0.7 |
| Ceramic vs. metal head | 1.1 (0.70–1.8) | 0.6 |
Adjusting variables are stratified by age group and side.
HR = hazard ratio. CI = confidence interval, OA = osteoarthritis,
RA = rheumatoid arthritis.
Indication for revision after new indications for revision were added at the data content revision: data starting from May 15, 2014, number (%)
| Main reason for revision | VEPE group | Reference group |
|---|---|---|
| Aseptic loosening | ||
| Cup | 1 (2) | 3 (3) |
| Stem | 3 (7) | 2 (2) |
| Osteolysis | ||
| Cup | 0 | 11 (12) |
| Stem | 0 | 3 (3) |
| Liner wear | 0 | 20 (22) |
| Component breakage | ||
| Cup | 0 | 1 (1) |
| Liner | 2 (5) | 3 (3) |
| Modular neck | 0 | 0 |
| Infection | 9 (21) | 5 (6) |
| Dislocation | 14 (33) | 21 (23) |
| Component malposition | ||
| Cup | 2 (5) | 4 (4) |
| Periprosthetic fracture | ||
| Acetabulum | 0 | 1 (1) |
| Femur | 6 (14) | 15 (17) |
| Unexplained pain | 1 (2) | 0 |
| Leg length discrepancy repair | 2 (5) | 0 |
| Other | 3 (6) | 1 (1) |
No data available concerning indication for revision from 27 revisions.